



FLORE Repository istituzionale dell'Università degli Studi di Firenze

St. John's Wort reduces neuropathic pain through a hypericinmediated inhibition of the protein kinase C γ and ϵ activity

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

Original Citation:

St. John's Wort reduces neuropathic pain through a hypericin-mediated inhibition of the protein kinase C γ and ϵ activity / Nicoletta Galeotti;Elisa Vivoli;Anna Rita Bilia;Franco Francesco Vincieri;Carla Ghelardini. - In: BIOCHEMICAL PHARMACOLOGY. - ISSN 0006-2952. - STAMPA. - 79:(2010), pp. 1327-1336. [10.1016/j.bcp.2009.12.016]

Availability: This version is available at: 2158/779593 since:

Published version: DOI: 10.1016/j.bcp.2009.12.016

Terms of use: Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf)

Publisher copyright claim:

(Article begins on next page)



Contents lists available at ScienceDirect

Biochemical Pharmacology



journal homepage: www.elsevier.com/locate/biochempharm

St. John's Wort reduces neuropathic pain through a hypericin-mediated inhibition of the protein kinase C γ and ϵ activity

Nicoletta Galeotti^{a,*}, Elisa Vivoli^a, Anna Rita Bilia^b, Franco Francesco Vincieri^b, Carla Ghelardini^a

^a Department of Preclinical and Clinical Pharmacology, University of Florence, Viale G. Pieraccini 6, I-50139 Florence, Italy ^b Department of Pharmaceutical Sciences, University of Florence, via U. Schiff 6, 50019 Sesto Fiorentino, Florence, Italy

ARTICLE INFO

Article history: Received 21 October 2009 Accepted 15 December 2009

Keywords: Hypericum perforatum St. John's Wort Neuropathic pain Hypericin Hyperforin PKC

ABSTRACT

Current pharmacological treatments for neuropathic pain have limited efficacy and severe side-effect limitations. St. John's Wort (SJW) is a medicinal plant, mainly used as antidepressant, with a favourable side-effect profile. We here demonstrate the ability of SJW to relieve neuropathic pain in rat models. The antihyperalgesic profile and mechanism of action of SIW and its main components were studied in two rat models of neuropathic pain: the chronic constriction injury and the repeated administration of oxaliplatin. SJW, acutely administered at low doses (30-60 mg kg⁻¹ p.o.), reversed mechanical hyperalgesia with a prolonged effect, being effective up to 180 min after injection. Further examinations of the SIW main components revealed that hyperform and hypericin were responsible for the antihyperalgesic properties whereas flavonoids were ineffective. The effect of SJW on the PKC expression and activation was investigated in the periaqueductal grey (PAG) area by immunoblotting experiments. Mechanistic studies showed a robust over-expression and hyperphosphorylation of the PKCy $(227.0 \pm 15.0\%$ of control) and PKC ϵ (213.9 ± 17.0) isoforms in the rat PAG area. A single oral administration of SJW produced a significant decrease of the PKC γ (131.8 \pm 10.0) and PKC ϵ (105.2 \pm 12.0) phosphorylation in the PAG area due to the presence of hypericin. Furthermore, SJW showed a dual mechanism of action since hyperforin antinociception involves an opioid-dependent pathway. Rats undergoing treatment with SJW and purified components did not show any behavioural side effects or signs of altered locomotor activity. Our results indicate SJW as a prolonged antihyperalgesic treatment through inhibition of PKC isoforms and their phosphorylation.

© 2009 Elsevier Inc. All rights reserved.

1. Introduction

Neuropathic pain can arise from a wide variety of injuries to peripheral or central nerves, including metabolic disorders, traumatic injury, inflammation, and neurotoxicity, and is characterized by spontaneous pain, hyperalgesia and allodynia which can persist long after the initial injury is resolved [1]. Common causes of neuropathy are diabetes, herpes zoster infections, chronic or acute trauma, and neurotoxins. Neuropathic pain occurs frequently in cancer as it may result from tumor invasion of nervous tissue, surgical nerve damage during tumor removal, radiation-induced nerve damage or as a side effect of many chemotherapeutic drugs [2,3].

The underlying molecular mechanisms of neuropathic pain are still not completely understood, and as a consequence, treatment is unsatisfactory in many cases [3,4]. Despite the large number of approved analgesic drugs, effective treatment of chronic pain is still often unattainable due to the unsatisfactory performance of the available drugs and due to the negative side effects from the drugs [5,6]. Neuropathic pain is generally insensitive to non-steroidal antiinflammatory drugs and relatively resistant to opioids, but can be treated by high opioid doses [7] with a high incidence of untoward side effects. The suggested treatment strategies for neuropathic pain management are represented by tricyclic antidepressants (TCAs)[8], that represent the first medication category proved to be effective for neuropathic pain in clinical trials [9] and still are a first choice treatment, anticonvulsants [10,11], antiarrythmics [12]. All these drugs have limited efficacy and have severe side effects. In particular, TCAs induce numerous untoward effects such as sedation, anticholinergic effects like dry mouth, constipation and postural hypotension, weight gain, greater risk to develop myocardial infarction [13,14]. Therefore, for an effective treatment of neuropathic pain, there is still a need to obtain therapeutics which possess a greater level of tolerability and safety.

Abbreviations: CCI, chronic constriction injury; CHL, chloroformic fraction; i.c.v., intracerebroventricular; i.p., intraperitoneal; MET, methanolic fraction; OXA, oxaliplatin repeated administration; p.o., per os; PAG, periaqueductal grey area; PKC, protein kinase C; PMA, phorbol-12-myristate-13-acetate; SJW, St. John's Wort; s.c., subcutaneous.

^{*} Corresponding author. Tel.: +39 055 4271312; fax: +39 055 4271280. *E-mail address*: nicoletta.galeotti@unifi.it (N. Galeotti).

^{0006-2952/\$ -} see front matter \circledcirc 2009 Elsevier Inc. All rights reserved. doi:10.1016/j.bcp.2009.12.016

Hypericum perforatum L., commonly known as St. John's Wort (SJW), has been proven to relieve mild-to-moderate forms of depression and tests have also shown SJW to have favourable side effects [15]. The most common SJW preparations used are hydroalcoholic extracts of the aerial portion of the plant that contain at least ten different kinds of biochemical compounds [16]. SJW interacts with the monoaminergic system through different mechanisms: the MAO-inhibitory properties of SIW were mainly due to hypericin [17.18] whereas the inhibition of serotonin. dopamine and noradrenaline synaptosomal uptake is related to the presence of hyperforin [19-22]. It has therefore been suggested that SJW may induce antidepressant activity through a mechanism similar to TCAs [23]. This evidence may suggest that similar to TCAs, SJW can also relieve neuropathic pain. The aim of the present study was to investigate the antihyperalgesic properties of SJW in different animal models, which were suffering from neuropathic pain that was induced by chronic constriction injury of the sciatic nerve, or by the repeated administration of the chemotherapeutic agent oxaliplatin. The role of the SJW main constituents, hypericin, hyperforin and flavonoids, and their cellular and molecular effects in the modulation of the pain threshold was also investigated in comparison with the effects produced by the SJW dried extract in order to better elucidate the mechanism of action in this herbal plant.

2. Materials and methods

2.1. Animals

Male Sprague–Dawley albino rats (180–200 g) from Harlan (S. Piero al Natisone, Italy) were used. Four rats were housed per cage. The cages were placed in the experimental room 24 h before the test for acclimatization. The animals were fed a standard laboratory diet and tap water *ad libitum* and kept at 23 ± 1 °C. The rats had a 12-h light/dark cycle, light at 7 AM. All experiments were carried out in accordance with the NIH Guide for the Care and Use of Laboratory Animals. All efforts were made to minimize animal suffering, and to reduce the number of animals used.

2.2. Production of neuropathy

2.2.1. Chronic constriction injury

A peripheral mono neuropathy was produced in adult rats by placing loosely constrictive ligatures around the common sciatic nerve according to the method described by Bennett and Xie [24]. Rats were anesthetized with chloral hydrate. The common sciatic nerve was exposed at the level of the middle of the thigh by blunt dissection through biceps femoris. Proximal to sciatica's trifurcation, about 1 cm of the nerve was freed of adhering tissue and four ligatures (3/0 chromic tread) were tied loosely around it with about 1 mm spacing. The length of the affected nerve was 4-5 mm long. Great care was taken to tie the ligatures such that the diameter of the nerve was barely constricted when viewed with $40 \times$ magnification. In shamoperated animals, an identical dissection was performed, but the sciatic nerve was not ligated. The ligation was made on the right paws and left paws were untouched. Experiments were carried out 14 days after surgery.

2.2.2. Oxaliplatin repeated treatment

Oxaliplatin was dissolved in a 5% glucose solution at a concentration of 2.4 mg kg⁻¹. Oxaliplatin was administered i.p. for five consecutive days per week for three consecutive weeks according to a previously established protocol [25]. The control group received a 5% glucose solution. The experiments were carried out on day 21.

2.3. Paw pressure test

The instrument has a cone-shaped pusher and exerts a force which is applied at a constant rate (32 g per s) on the upper surface of the rat hind paw. The force is continuously monitored by a pointer which moves along a linear scale. The pain threshold is given by the force which first induces struggling from the rat. An arbitrary cut off value of 250 g was adopted. Those rats scoring <40 g or over 75 g in the pretest, performed before chronic constriction injury or oxaliplatin administration, were rejected (25%). The pain threshold of neuropathic animals was measured previously (pretest) and then 30, 60, 90, 120 and 180 min after administration of SJW and components.

2.4. Rota rod test

The apparatus consisted of a base platform and a rotating rod with a diameter of 3 cm and a non-slippery surface. The rod, 30 cm in length, was placed at a height of 15 cm from the base. Up to five rats were tested simultaneously on the apparatus, with a rod-rotating speed of 16 rpm. The integrity of motor coordination was assessed on the basis of the number of falls from the rod in 30 s. Those rats scoring less than three and more than six falls in the pretest were rejected (20%). Their performance time was measured previously (pretest) and then 60, 90 and 120 min after SJW, CHL and MET fractions or purified components administration. A total of 4–5 rats per group were tested.

2.5. I.c.v. injection technique

Intracerebroventricular (i.c.v.) administration was performed under ether anesthesia with isotonic saline as a solvent which has been previously described [26].

2.6. Preparation of membrane and cytosol fractions

Rat periaqueductal grey (PAG) area was dissected and homogenized in a homogenizing buffer. The homogenate was centrifuged at 9000 × g for 15 min at 4 °C and the low speed pellet was discarded. The supernatant (total proteins) was centrifugated at 100,000 × g for 60 min at 4 °C. The resulting supernatant was the cytosol fraction, and the pellet was resuspended in the homogenizing buffer containing 0.2% (wt/vol) Triton X-100. The homogenate was kept at 4 °C for 60 min with occasional stirring and then centrifugated at 100,000 × g for 60 min at 4 °C. The resulting supernatant was used as the membrane fraction. Protein concentration of the cytosol and membrane fractions was quantified using Bradford's method (protein assay kit, Bio Rad Laboratories, Milan, Italy).

2.7. Immunoblot analysis

Membrane homogenates (10–50 µg) of naïve, untreated CCI and SWJ treated CCI rats were separated on 10% SDS-PAGE and transferred onto nitrocellulose membranes (100 min at 100 V) using standard procedures. The membranes were blocked in PBST (PBS containing 0.1% Tween) containing 5% nonfat dry milk for 90 min. Following washings, blots were incubated overnight at 4 °C with specific antibodies (Santa Cruz Biotechnology, CA, USA) against PKC γ , p-PKC γ , PKC ϵ , p-PKC ϵ or β -actin (1:1000 dilution). After being washed with PBST, the nitrocellulose membranes were incubated with goat anti-rabbit horseradish peroxidase-conjugated secondary antisera (1:5000) and left for 90 min at room temperature. Blots were then extensively washed according to the manufacturer's instruction and developed using enhanced chemiluminescence detection system (Pierce, Milan, Italy). The

exposition and developing times used were standardized for all the blots. Densitometric analysis of scanned images was performed on a Macintosh iMac computer using the public domain NIH Image program. Measurements in control samples were assigned a relative value of 100%. Measurements were normalised relative to β -actin, used as loading control.

2.8. HPLC-DAD and HPLC-MS drug analyses

To evaluate the content of SJW main components, a HPLC analysis was performed using a method described in the [27], modified for our experimental requirements. The identification of the constituents was performed using combined HPLC-diode array detection (DAD) analysis and HPLC-thermospray mass spectrometry. The mobile phase was a five-step linear solvent gradient $CH_3CN/CH_3OH/H_2O$ (pH 3.2, HCOOH) over a 60 min period at a flow rate of 1 ml/min. The quantification of the constituents was performed using rutin as an external standard and consideration of each constituent and the relative response factor (RRF) with respect to the rutin, as previously reported [27].

All the samples were analyzed in triplicate and a calibration graph with six data points of external standard was used.

2.9. Preparation of chloroform and methanol fractions

A solution of dried SJW extract (1 g) in 10 ml of chloroform was stirred for 3 h in the dark. The mixture was filtered and the solution was evaporated to obtain a residue of 200 mg, containing the pholoroglucinols as confirmed by HPLC-DAD-ESI-MS analysis.

The residue present on the filter was washed with 10 ml of methanol. The methanol solution was evaporated and a residue of 700 mg was obtained. The HPLC-DAD–ESI-MS analysis showed in this fraction only the presence of flavonoids and naphthodian-thrones.

2.10. Drugs

Indena Research Laboratories (Settala, Milan, Italy) offered a commercial sample of *Hypericum perforatum* dried extract – Lotto 28662/M1 – B.A. 84204 and kindly provided the reference rutin trihydrate (batch no. K12408717, standard purity 96.25% considering the content of residual solvents, moisture and amount of impurities).

The following drugs were used: oxaliplatin (Sequoia Research Product Ltd., USA), naloxone hydrochloride, hypericin, hyperforin, hyperoside, quercetin, amentoflavone, amitriptyline hydrochloride (Sigma, Milan, Italy); phorbol-12-myristate-13-acetate (PMA), (Calbiochem, Milan, Italy); and carboxymethylcellulose sodium salt, (CMC) (Fluka Chemie GmbH, Steinheim, Germany). The other commercially available chemicals used were of the highest quality.

SJW dried extract, chloroform fraction (CHL), methanol fraction (MET), hypericin, hyperforin, quercetin, hyperoside and amentoflavone were dissolved in a 1% CMC solution immediately before use and administered by oral gavage. Naloxone and amitriptyline were dissolved in isotonic (NaCl 0.9%) saline solution, PMA was dissolved in 0.1% DMSO immediately before use. Drug concentrations were prepared to ensure that the necessary dose could be administered in a volume of 10 ml kg⁻¹ by intraperitoneal (i.p.), per os (p.o.) injection or in a volume of 5 μ l by i.c.v. injection.

2.11. Drug administration

SJW dried extract, CHL and MET fractions, hypericin, hyperforin, quercetin, hyperoside and amentoflavone were administered 90 min before the paw pressure test, in correspondence to their maximum effect as determined by time-course experiments.

The SJW components were orally administered 90 min before the test at the following doses: hypericin 0.06 mg kg⁻¹, hyperforin 0.978 mg kg⁻¹, quercetin 0.249 mg kg⁻¹, hyperoside 1.905 mg kg⁻¹ and amentoflavone 0.016 mg kg⁻¹. These doses correspond to the amount of each component present in a 30 mg kg⁻¹ preparation of SJW dried extract. CHL and MET fractions were administered in a concentration containing the above-mentioned content of their main components, hyperforin and hypericin respectively. The effect of amitriptyline was evaluated 30 min after administration.

Naloxone (1 mg kg⁻¹ i.p.) was injected 70 min after SJW, CHL or MET administration. PMA (15 pmol per mouse i.c.v.) was injected 30 min after SJW, CHL or MET administration.

The doses and administration schedules of SJW and all other drugs used were chosen on the bases of time-course and doseresponse experiments previously performed in our laboratory.

2.12. Statistical analysis

All experimental results are given as the mean \pm s.e.m. An analysis of variance (ANOVA), followed by Fisher's Protected Least Significant Difference procedure for post hoc comparison, were used to verify significance between two means.

3. Results

3.1. Composition of SJW dried extract, chloroform and methanol fractions

The main components of SJW dried extract were flavonoids (12.72%), phloroglucinols (4.23%) and naphthodianthrones (0.32%), as reported in Table 1. In order to investigate the role of these components in the mechanism of action of SJW, a chloroform and a methanol fraction were obtained from the dried extract. The chloroform fraction (CHL) contained phloroglucinols whereas the methanol fraction (MET) showed the presence of naphthodiantrones and flavonoids representing a hypericin and flavonoid rich fraction (Table 1).

Table 1

Composition of the SJW dried extract, CHL and MET fractions.

Constituent	Content % (mg/100 mg)		
	SJW	CHL	MET
Flavonoids			
Rutin	4.28		
Hyperoside	6.35		
Isoquercitrin	0.61		
Rutin, hyperoside, isoquercitrin		n.d.	9.29
Quercitrin	0.65	n.d.	0.69
Quercetin	0.83	n.d.	0.42
I3,II8-biapigenin	0.62	0.29	0.25
Total flavonoids	12.72		
Phloroglucinols			
Oxyhyperforin		1.16	n.d.
Furohyperforin		1.21	n.d.
Hyperforin		12.49	n.d.
Adhyperforin		1.34	n.d.
Total Phloroglucinols	4.23		
Naphthodianthrones			
Pseudohypericin		0.04	0.11
Hypericin		0.01	0.20
Total naphthodianthrones	0.32		

CHL: chloroform fraction; MET: methanol fraction. The content of each constituent is expressed as percentage (mg/100 mg).



Fig. 1. Dose–response curves for the antinociceptive and antihyperalgesic effect of SJW dried extract in the chronic constriction injury of the sciatic nerve (CCI) and repeated oxaliplatin treatment (OXA) rat model of neuropathic pain. (a) Dose–response curve of SJW dried extract (1–100 mg kg⁻¹ p.o.) for the antinociceptive (uninjured leg; SJW 10 mg kg⁻¹ p.o., F(1,22) = 6.730, p < 0.05; SJW 30 mg kg⁻¹ p.o., F(1,17) = 35.317, p < 0.001) and antihyperalgesic (injured leg; SJW 30 mg kg⁻¹ p.o., F(4,44) = 10.690, p < 0.001) effect in the CCI rats. Data were recorded 90 min after SJW administration. Experiments were performed 14 days after surgery when a significant mechanical hyperalgesia was obtained (F(1,19) = 44.631, p < 0.001) in comparison with values recorded before treatment in the corresponding leg; 'p < 0.001 in comparison with values recorded before treatment in comparison with CMC-treated group. (c) Time–course curve of SJW dried extract (30 mg kg⁻¹ p.o.) for the antinociceptive activity in naïve rats. *p < 0.01 in comparison with CMC-treated group. (c) Time–course curve of the mechanical hyperalgesia induced by repeated administration of oxaliplatin in comparison with saline-treated rats. A statistically significant hyperalgesia appeared on day 21 (F(1,14) = 22.345, p < 0.001); *p < 0.001 compared to saline control group. (d) Dose–response curve of SJW dried extract (10–100 mg kg⁻¹ p.o.) for the antinociceptive (saline-treated group; SAL) and antihyperalgesic (OXA; F(4,42) = 12.718, p < 0.001) effect in the rat OXA model of neuropathic pain. Data were recorded 90 min after SJW administration. *p < 0.001 in comparison with corresponding values recorded before treatment, 'p < 0.001 compared to saline control group. The extinction of submission with saline-treated group; SAL) and antihyperalgesic (OXA; F(4,42) = 12.718, p < 0.001) compared to saline control group. The extinction *p < 0.001 compared to saline control group. The extinction *p < 0.001 co

3.2. Antihyperalgesic/antinociceptive activity of SJW dried extract in rat models of neuropathic pain

Two different rat models of neuropathic pain were used: chronic constriction injury of the sciatic nerve (CCI) and oxaliplatin repeated administration (OXA). CCI, 14 days after surgery, induced mechanical hyperalgesia (rat paw pressure test) as demonstrated by the reduced pain threshold in the hind paw affected by CCI in comparison with the controlateral uninjured leg (Fig. 1a F(1,19) = 44.631, p < 0.001). Pain threshold values comparable to those recorded in the controlateral uninjured leg were detected in the sham-operated before (65.0 \pm 5.5) and after (64.6 ± 3.3) a single oral administration of CMC. Same results were obtained in naïve rats (Fig. 1b). Similarly to CCI, oxaliplatin repeated administration induced the development of neuropathic pain as illustrated by nociceptive behaviour as compared with the salinetreated control group. A statistically significant hyperalgesia appeared on day 21, persisted unmodified up to day 27 and then it diminished (Fig. 1c).

A single administration of SJW dried extract dose-dependently $(1-100 \text{ mg kg}^{-1} \text{ p.o.})$ reversed the mechanical hyperalgesia in both models of neuropathic pain: CCI (Fig. 1a) and OXA (Fig. 1d). The antihyperalgesic effect appeared at antinociceptive doses: the dose of 1 mg kg⁻¹ p.o. was devoid of any effect, at 10 mg kg⁻¹ p.o. SJW significantly increased the rat pain threshold peaking at 30 mg kg⁻¹ p.o. At higher concentrations, the antihyperalgesic

effect diminished showing a bell-shaped trend (Fig. 1a and d). The SJW antihyperalgesic effect was of similar intensity to that produced by amitriptyline (10 mg kg⁻¹ i.p.; 80.3 ± 4.2), used as reference drug. Time-course experiments showed that the antinociceptive (Fig. 2a and c) and the antihyperalgesic (Fig. 2b and c) effects of SJW (30 mg kg⁻¹ p.o.) share the same profile: they both became statistically significant 30 min after oral administration, peaked at 90 min, persisted up to 120 min and disappeared at 180 min in all of the rat models tested for neuropathic pain. In the sham-operated rats SJW (30 mg kg⁻¹ p.o.) increased the pain threshold (controlateral 110.1 ± 3.1: sham-operated 108.8 ± 5.6) with similar intensity to that observed in naïve rats (Fig. 1b) and in the controlateral uninjured leg of CCI rats (Fig. 2a).

The effect produced by a single oral administration of SJW on rat pain threshold was investigated in the rat paw pressure test. Administration of drugs by oral gavage can be a stressful procedure for the animal and currently it is not possible to critically evaluate the extent to which some of the drug effects observed might be due to stress-induced analgesia associated with handling and injection of rats. An orally administered vehicle group (CMC) was, therefore, included in the study. A dried extract of SJW (30 mg kg⁻¹ p.o.) showed antinociceptive activity against a mechanical stimulus in naïve rats in comparison with CMC-treated animals, used as control group (Fig. 1b). A single p.o. administration of CMC did not alter the pain threshold in comparison with the pre-treatment values (Fig. 1b).



Fig. 2. Time-course curves for the antinociceptive and antihyperalgesic effect of SJW dried extract in rat models of neuropathic pain induced by chronic constriction injury of the sciatic nerve (CCI) and repeated administration of oxaliplatin (OXA). Time-course curves of SJW dried extract (30 mg kg⁻¹ p.o.) in the CCI model for the antinociceptive (uninjured leg) (a) and antihyperalgesic (injured leg) (b) effect. **p* < 0.05 in comparison with CMC-treated group. All data are presented as mean ± s.e.m. (c) Time-course curves of SJW dried extract (30 mg kg⁻¹ p.o.) in the OXA model for the antinociceptive (SAL) and antihyperalgesic (OXA) effect. **p* < 0.05 in comparison with SAL before treatment; ^*p* < 0.05 in comparison with OXA before treatment. All data are presented as mean ± s.e.m. The experiments were carried out on day 21.

A dried extract of SJW induced a dose-dependent (1– 100 mg kg⁻¹ p.o.) mechanical antinociception also in the uninjured non-hyperalgesic leg of CCI rats. The dose of 1 mg kg⁻¹ p.o. was devoid of any effect (F(1,14) = 2.714, p = 0.121). At 10 mg kg⁻¹ p.o. SJW significantly increased the rat pain threshold. The antinociceptive effect peaked at 30 mg kg⁻¹ p.o. and then it diminished (Fig. 1a).

SJW was also able to increase the pain threshold in rats treated for 21 days with a daily injection of saline solution, animals that represented the control group of the oxaliplatin-treated rats (Fig. 1d). Time-course experiments confirmed the prolonged effect

3.3. Analgesic and antihyperalgesic activity of SJW components

The chloroform fraction (CHL), representing a hyperforin rich fraction, induced antinociception when administered in a concentration corresponding to the content of hyperforin present in a 30 mg kg⁻¹ preparation of SJW dried extract. The CHL-induced increase of the pain threshold was observed in the uninjured leg of rat with CCI (Fig. 3a) as well as in naïve rats (88.8 \pm 4.7). The CHL antinociceptive dose was also endowed with antihyperalgesic activity. CHL significantly reversed the hyperalgesia in CCI and OXA rat models. The effect produced by CHL administration in CCI rats, taken as example, was reported in Fig. 3a. Conversely, the methanol fraction (MET), a hypericin/flavonoid rich fraction, selectively induced antihyperalgesia without changing the baseline mechanical threshold in control rats (lack of antinociceptive properties). MET, administered in a concentration corresponding to the content of hypericin present in a 30 mg kg^{-1} preparation of SJW dried extract, selectively reversed the mechanical hyperalgesia in the hind paw affected by CCI (Fig. 3b) as well as in the OXA model (Fig. 3c) by increasing the pain threshold up to values comparable to the control ones. Time-course experiments showed that CHL and MET were endowed with the same pharmacological profile of the SJW dried extract (Fig. 3a-c). Purified hyperform, when administered alone, produced an antinociceptive/antihyperalgesic effect of intensity comparable to CHL fraction (Fig. 4a). Similarly, purified hypericin reversed the mechanical hyperalgesia up to a value comparable to that produced by MET fraction (Fig. 4b). The purified flavonoids amentoflavone (AME) and hyperoside (HypS) neither showed antinociceptive/antihyperalgesic properties (Fig. 4c) nor increased hypericin-induced antihyperalgesia (Fig. 4d). Quercetin (QUER) produced a significant antihyperalgesic activity even if of lower intensity than hypericin (Fig. 4c), but it was unable to potentate hypericin effect (Fig. 4d).

3.4. Mechanism of antinociceptive/antihyperalgesic action of SJW dried extract and components

SJW dried extract antinociception $(30 \text{ mg kg}^{-1} \text{ p.o.})$ was prevented by the opioid antagonist naloxone $(1 \text{ mg kg}^{-1} \text{ i.p.})$ whereas the antihyperalgesic activity was only slightly reduced (Fig. 5a). The increase of pain threshold as well as the prevention of the hyperalgesia produced by CHL was completely antagonized by pre-treatment with the opioid antagonist naloxone (Fig. 5b). Conversely, the antihyperalgesia induced by MET was naloxone insensitive (Fig. 5c). The administration of the PKC activator PMA (15 pmol per mouse i.c.v.) significantly reduced the SIW dried extract (30 mg kg⁻¹ p.o.) antihyperalgesic activity whereas the antinociception was only slightly reduced (Fig. 6a). PMA selectively prevented the antihyperalgesic effect induced by MET (Fig. 6b), but was devoid of any effect against the CHL-induced increase of pain threshold (Fig. 6c). Similar results were obtained by administering purified hyperforin and hypericin (data not shown). The opioid antagonist naloxone as well as the PKC activator PMA, at the concentrations used, were devoid of any antinociceptive/hypernociceptive effect (71.7 \pm 4.7; 72.0 \pm 1.7, respectively). The dose of naloxone of 1 mg kg^{-1} has been demonstrated to prevent morphine analgesia without modifying the increase of the pain threshold induced by modification of other neurotransmission systems (i.e. GABAergic, muscarinic, serotoninergic, etc.). Higher naloxone doses were not employed since lacking of selectivity toward opioid analgesia.



Fig. 3. Antinociceptive profile of SJW fractions containing the SJW major components in rat models of neuropathic pain. (a) Antinociceptive (uninjured leg; F(3,35) = 5.422, p < 0.001) and antihyperalgesic (injured leg) effect of the chloroform (CHL) fraction, administered in an amount containing 0.978 mg kg⁻¹ hyperforin, in the CCI model. Data are presented as mean \pm s.e.m.; *p < 0.001 in comparison with the uninjured leg before treatment; $^{h}p < 0.01$ in comparison with the injured leg before treatment. (b) Antihyperalgesic (injured leg; F(3,32) = 6.002, p < 0.001) effect of the methanol (MET) fraction (30 mg kg⁻¹), administered in an amount containing 0.06 mg kg⁻¹ hypericin, in the CCI model. Data are presented as mean \pm s.e.m.; *p < 0.001 in comparison with uninjured leg before treatment; $^{h}p < 0.05$ in comparison with injured leg before treatment. (c) MET prevented the mechanical hyperalgesia induced by oxaliplatin (OXA; F(3,33) = 7.244, p < 0.001) administration without inducing antinociception in the saline (SAL) group. Data are presented as mean \pm s.e.m.; *p < 0.001 in comparison with SAL; $^{h}p < 0.001$ in comparison with OXA. The experiments were carried out on day 21.

Rats underwent CCI operation showed increased levels of PKC γ and PKC ϵ (Fig. 6d) isoforms in the PAG area. This effect was detected in the total protein preparation (TOT), in the membrane (MEM) and cytosol (CYT) fractions. A robust increase of the phosphorylation of PKC γ and PKC ϵ was also observed in the total proteins (TOT) (PKC γ : *F*(1,10) = 15.536, *p* < 0.001; PKC ϵ : *F*(1,10) = 18.196, *p* < 0.001) and in the membrane fraction (MEM) whereas in the cytosol fraction (CYT) the levels of p-PKC γ and p-PKC ϵ were similar to the control group (Fig. 6d). SJW treatment was able to reduce the phosphorylation of both PKC



Fig. 4. Antinociceptive profile of purified components of CHL and MET fractions in the CCI model of neuropathic pain. (a) Purified hyperforin (0.978 mg kg⁻¹) showed antinociceptive (uninjured leg) and antihyperalgesic (injured leg) properties with a similar profile to CHL (F(3,32) = 4.871, p < 0.001). Data are presented as mean \pm s.e.m.. *p < 0.001 in comparison with uninjured leg before treatment; $^{\wedge}p < 0.05$ in comparison with injured leg before treatment. (b) Hypericin (0.06 mg kg⁻¹), similarly to MET, reversed the mechanical hyperalgesia (injured leg; F(3,35) = 3.992, p < 0.001) without increasing the pain threshold in the non-hyperalgesic (uninjured) leg. Data are presented as mean \pm s.e.m.; *p < 0.001 in comparison with uninjured leg before treatment; $^{\wedge}p < 0.001$ in comparison with uninjured leg before treatment; $^{\wedge}p < 0.001$ in comparison with uninjured leg before treatment; $^{\wedge}p < 0.001$ in comparison with uninjured leg before treatment; $^{\wedge}p < 0.001$ in comparison with uninjured leg before treatment; $^{\wedge}p < 0.001$ in comparison with uninjured leg before treatment; $^{\circ}p < 0.001$ in comparison with uninjured leg before treatment; $^{\circ}p < 0.001$ in comparison with uninjured leg before treatment; $^{\circ}p < 0.001$ in comparison with uninjured leg before treatment; $^{\circ}p < 0.001$ in comparison with uninjured leg before treatment; $^{\circ}p < 0.001$ in comparison with uninjured leg before treatment; $^{\circ}p < 0.05$. Data are presented as mean \pm s.e.m.; Data were recorded 90 min after administration of SJW constituents. *p < 0.01 in comparison with uninjured leg before treatment; (QUER) were unable to potentate the hypericin-induced antihyperalgesic effect. Data were recorded 90 min after administration of SJW constituents. Data are presented as mean \pm s.e.m. *p < 0.01 in comparison with injured leg before treatment; $^{\circ}p < 0.05$ in comparison with injured leg before treatment. Each component was administered at a dose corresponding to the amount of each componen



Fig. 5. Involvement of the opioid system in the antinociceptive activity of SJW and CHL fraction in the CCI model of neuropathic pain. (a) Prevention by naloxone (1 mg kg⁻¹ i.p.) of SJW dried extract (30 mg kg⁻¹ p.o.) antinociception (naïve, shamoperated, uninjured leg; F(1,18) = 9.487, p < 0.001). Lack of effect on the antihyperalgesic activity (injured leg; F(1,14) = 2.714, p = 0.121). Data were recorded 90 min after administration of SIW. Data are presented as mean \pm s.e.m.; **p* < 0.001 in comparison with uninjured leg before treatment; $^{\wedge}p < 0.01$ in comparison with injured leg before treatment. (b) Prevention by naloxone of CHL (administered in a dose containing 0.978 mg kg⁻¹ hyperforin) antinociception (naïve, sham-operated, uninjured leg; F(1,16) = 8.422, p < 0.001) and antihyperalgesia (injured leg; F(1,16) = 5.612, p < 0.01). Data were recorded 90 min after administration of CHL. Data are presented as mean \pm s.e.m.; *p < 0.05 in comparison with uninjured leg before treatment; $^{p} < 0.05$ in comparison with injured leg before treatment. (c) Lack of effect of naloxone on MET (administered in a dose containing 0.06 mg kg⁻¹ hypericin) antihyperalgesia (injured leg). Data were recorded 90 min after administration of MET. Data are presented as mean \pm s.e.m.; *p < 0.05 in comparison with uninjured leg before treatment; $^{p} < 0.05$ in comparison with injured leg before treatment.

isoforms as demonstrated by the decrease of $p-PKC\gamma$ and $p-PKC\epsilon$ levels up to values corresponding to the control (Fig. 6d). Similar results were obtained in the PAG of OXA rats (data not shown).

Immunoblots were re-probed for a protein considered to be not regulated as β -actin and no significant density difference was revealed for this protein among samples.

Cross-reactivity of the primary antibodies used was excluded.

3.5. Effects of SJW dried extract and fractions on rat locomotor behaviour

The SJW dried extract, CHL and MET fractions were tested, at the highest effective doses, in order to assess their effect on rat locomotor behaviour. Rats pretreated with the above-mentioned extracts at the dose of 30 mg kg⁻¹ p.o. were evaluated for motor coordination by use of the rota rod test. The number of falls from the rotating rod, evaluated before and 60, 90 and 120 min after treatments, showed the lack of any impairment in the rat motor coordination by SJW dried extract and fractions administration in comparison with the control group (CMC) (Fig. 7a). Each group progressively reduced its number of falls because mice learned how to balance on the rotating rod.

Amitriptyline, used as antinociceptive reference drug, at the dose of 10 mg kg⁻¹ did not impair the motor coordination of rats. Conversely, at a 3 times higher dose (30 mg kg⁻¹), it produced an increase in the number of falls from the rotating rod indicating the presence of motor incoordination (Fig. 7a). SJW, at a dose of 1000 mg kg⁻¹ was still devoid of any side effect (Fig. 7a). Similarly, purified hypericin, hyperforin, quercetin, hyperoside and amento-flavone, administered at a concentration corresponding to the content present in 30 mg kg⁻¹ p.o. preparation of SJW dried extract, were devoid of any effect on the locomotor behaviour (Fig. 7b).

4. Discussion

We report here the first description of the capability of a SJW dried extract to reduce hyperalgesia in rat models of neuropathic pain after a single oral administration.

Painful neuropathy is a condition that may develop when nerve fibres are damaged or dysfunctional. Since it can arise from a wide variety of injuries, two different models of neuropathic pain were used. The chronic constriction injury of the sciatic nerve was used as a model of neuropathy being induced by nerve damage whereas the repeated administration of oxaliplatin represented a chemotherapy-induced neuropathic pain model. A single oral administration of SJW reversed mechanical hyperalgesia in both models of neuropathic pain producing a prolonged increase of the pain threshold that continued up to 120 min. The efficacy of SJW in the management of neuropathic pain, regardless of the kind of injury responsible for the painful condition, was suggested. A clinical study conducted in patients suffering from painful polyneuropathy reported a trend of lower pain scores when treated with SJW than did the patients who were treated with a placebo. A statistically significant relief of pain was not obtained [28], and this discrepancy might be explained by considering that the SJWinduced antinociception has a bell-shaped trend. The authors looked for an increase of the pain threshold at a concentration (2.7 mg/die total hypericins) similar to that which was employed in trials with depressed patients. This concentration was about 30 times higher than the analgesic concentration (0.096 mg total hypericins) and, as demonstrated by dose-response experiments, at this level the antinociceptive efficacy of SIW is strongly reduced.

At doses able to reverse hyperalgesia, SJW-induced mechanical antinociception in untreated non-painful rats (control groups) as well as in the controlateral uninjured hind limbs of CCI rats. These reports confirm and support the hypothesis for the role that SJW has in the modulation of pain perception. This hypothesis has been suggested in a recent paper that indicates the antinociceptive properties of SJW in the mouse formalin test [29].

The main components of the SJW dried extract are phloroglucinols, naphthodiantrones and flavonoids. The effects produced by these constituents were investigated in order to discover the components responsible for the antinociceptive activity and to better elucidate the SJW mechanism of analgesic action. We obtained a chloroform fraction (CHL) containing phloroglucinols, mainly represented by hyperforin, and a methanol fraction (MET) that was a hypericin and flavonoid rich fraction. CHL fraction reversed the mechanical hyperalgesia in all neuropathic pain models and increased the pain threshold in the control non-painful



Fig. 6. Blockade of the PKC activity as mechanism of the antihyperalgesic effect of SJW and MET fraction in the CCI model of neuropathic pain. (a) The administration of the PKC activator PMA (15 pmol per mouse i.c.v.) significantly reduced the SJW dried extract (30 mg kg⁻¹ p.o.) antihyperalgesic activity (F(1,14) = 5.729, p < 0.001) whereas the antinociception was only slightly reduced (F(1,14) = 2.714, p = 0.0487). Data were recorded 90 min after administration of SJW. (b) Prevention by the PKC activator PMA of MET antihyperalgesic activity (injured leg; F(1,15) = 6.231, p < 0.001). Data were recorded 90 min after administration of MET. (c) Lack of effect of PMA on the CHL-induced antinociception (uninjured leg) and antihyperalgesia (injured leg). Data were recorded 90 min after administration of CHL. Data are presented as mean \pm s.e.m.; *p < 0.001 in comparison with uninjured leg; P < 0.01 in comparison with injured leg. (d) The CCI induced an increase in the PKC γ is oforms levels observed in the total protein preparation (TOT; PKC γ : F(1,10) = 3.991, p < 0.01; PKC ε : F(1,10) = 4.961, p < 0.01 and in the membrane (MEM) and cytosol (CYT) fractions from the periaqueductal grey (PAG) area of neuropathic rats. A dramatic increase of the phosphorylation of PKC γ and PKC ε isoforms up to control values. Densitometric values are reported as percentage of control. *p < 0.01 in comparison with control group; $^{8}p < 0.05$ in comparison with CCI.

animals. The intensity of the CHL fraction activity was lower than that of the SJW dried extract, but a similar time-course profile was observed. The MET fraction was as effective as the CHL in relieving neuropathic pain. This indicates that the SJW main components present in both fractions are responsible for the antihyperalgesic properties of the plant. It is interesting to note that MET, conversely to CHL, was devoid of any analgesic activity in the non-painful rats. These results might suggest a selective role of hypericin/flavonoid in the relief of neuropathic pain, rather than being effective as a direct result of their antinociceptive properties. The SJW antinociception underlies the activation of the opioid system as this analgesia is prevented by the opioid antagonist naloxone. Binding of [³H]naloxone to the μ - and k-opioid receptor was inhibited in the presence of SJW extract [30], further supporting a SJW opioid mechanism. Phloroglucinols might be responsible for this opioid effect since hyperforin inhibited binding to the opioid receptors with a higher affinity than hypericin and flavonoids [30,31]. The prevention by naloxone of CHL-induced antinociception further supports this hypothesis. CHL fraction contains phloroglucinols together with a small amount of the



Fig. 7. Lack of induction of locomotor side effects by SJW dried extract, fractions and purified components. (a) Lack of effect of SJW dried extract, CHL and MET fractions on rat motor coordination evaluated in the rat rota rod test. Effects produced by amitriptyline (AMI) at the doses of 10 and 30 mg kg⁻¹, used as reference antinociceptive drug. *p < 0.05 in comparison with CMC-treated rats. (b) Purified SJW main components showed the lack of any influence on locomotor behaviour. A total of 4–5 rats per group were tested.

flavonoid biapigenin that binds to the opioid receptor with a much lower affinity than hyperforin [31]. The administration of purified hyperforin produced an antinociceptive effect comparable to that induced by the CHL fraction, which further suggests the prominent role of hyperforin in the CHL activity.

The MET fraction contains hypericins and flavonoids, both of which might be potentially involved in the SJW mechanism of antinociceptive action. The total amount of hypericins add up to about 0.3% of the SJW dried extract and have long been known to be related to many pharmacological properties of SJW. Recent studies report antidepressive, antineoplastic, antitumor and antiviral activities of hypericin [18]. Flavonoids contribute to the anti-inflammatory effects of the plant [32] and antinociceptive properties have been reported for the flavonoid myricitrin [33]. Enzyme assays performed on rat brains demonstrated that hypericin and pseudohypericin are potent and selective inhibitors of the protein kinase C (PKC) [34,18]. In vitro studies reported that some flavonoids inhibit rat brain PKC activity. Among the flavonoids, quercetin is one of the most significant [35]. PKC is a family of enzymes involved in numerous important cellular events, including pain modulation. PKC integrates numerous receptor pathways into final effectors that increase excitatory signalling and decrease inhibitory signalling, thus inducing pain. The activation of PKC has been related to the induction of a painful condition whereas PKC blockers decreased nociception [36]. Pre-treatment with the PKC activator PMA antagonized the MET-induced antinociception, whereas with the CHL-induced, the increase of the pain threshold remained unmodified. Conversely to the CHL fraction, the MET fractions mechanical antihyperalgesia remains unmodified by the naloxone pre-treatment. These results suggest that a selective blockade of the PKC-mediated intracellular pathway underlies the MET activity.

PKC is a family of serine/threonine kinases that are divided into three groups based on calcium and diacylglycerol dependence: conventional (α , β I, β II, and γ), novel (δ , ϵ , η , and θ), atypical (ζ and λ/ι) [37]. Among them, PKC ϵ and PKC γ isoforms appear to play a prominent role in the modulation of pain perception [36,38,39]. In particular, the translocation of these enzymes from the cytosol to the synaptic membrane is thought to be necessary for their activation [40]. Increased translocation and activation of PKC in dorsal horn neurons has been shown in a number of pain models. This suggests the importance in the modulation of pain perception of spinally located PKC [36]. We have detected a specific upregulation of PKCy and PKCE isoforms in the PAG area of neuropathic rats along with a robust increase of the PKC γ and PKC ϵ phosphorylation. Furthermore, we discovered a lack of increase in any of the phosphorylation of PKC ε and PKC γ in the cytosol in comparison with the high phosphorylated form levels observed in the membrane fraction of neuropathic rats. These results have highlighted the importance of supraspinally located PKC in the modulation of the sensation of pain. This suggests that in the presence of neuropathies, the activation of the PKC-mediated pathway is not only confined to the spinal cord. The SJW oral administration produced a complete reversal of the phosphorylation of both PKC ε and PKC γ in the total protein preparation as well as in the membrane fraction. These data suggest the hypothesis of a PKC-inhibiting mechanism in SJW for antinociception and indicate the isoforms ε and γ of PKC as potential targets for this antinociceptive effect. Furthermore, the importance of the inhibition of the PKC activity in order to treat neuropathic pain is further confirmed.

To identify the MET component responsible for the increase of pain threshold, the effect produced by administration of purified MET fraction components was investigated. Hypericin showed antinociceptive properties of intensity comparable to that produced by the MET fraction. Conversely, hyperoside, which is the most abundant flavonoid present in the SJW dried extract, neither increased the pain threshold nor potentated the hypericininduced antinociception. Anti-inflammatory properties were reported for the flavonoid amentoflavone [41], but, when administered alone in neuropathic rats, it was devoid of any antinociceptive effect. Quercetin was unable to potentate hypericin antinociception when co-administered, even if it resulted in being slightly effective in increasing the pain threshold. This is not surprising since quercetin, which is similar to hypericin, has PKCblocking properties. A quercetin potency about 30 times lower [35] than hypericin [34] might explain the lower efficacy observed in behavioural tests. Hypericin appears, therefore, to be the most effective component of the MET fraction.

An important drawback of the current analgesic therapy of neuropathic pain is the high occurrence of side effects [42]. The potential induction of side effects by SJW and components at the doses able to increase the pain threshold was, therefore, investigated. In accordance with the literature data that indicate SJW as a medicinal plant with a favourable tolerability and safety profile [15], the SJW dried extract, CHL and MET fractions, at the highest active doses employed in the present study, caused neither detectable modification in the rats gross behaviour, nor did they alter their locomotive activity. Similar profile was also demonstrated by purified SJW main components.

In conclusion, our findings showed that a single oral administration of SJW, CHL and MET fractions, as well as purified hyperforin and hypericin, relieve neuropathic pain in rats with a very positive side-effects profile. This increase of the pain threshold is related to the modulation of two different intracellular pathways: the activation of the opioid system, underling the presence of hyperforin, which is responsible for the antinociceptive properties, and a PKC-mediated mechanism through the PKC-blocking properties of hypericin, mainly related to the antihyperalgesic activity. Finally, these results further support the hypothesis that the inhibition of PKC specific isoforms might be a promising strategy for effective treatment of neuropathic pain.

Acknowledgement

This work was supported by grants from MIUR.

References

- Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999;353:1959–64.
- [2] Cruccu G, Anand P, Attal N, Garcia-Larrea L, Haanpää M, Jørum E, et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol 2004;11:153–62.
- [3] Hansson PT, Dickenson AH. Pharmacological treatments of peripheral neuropathic pain conditions based on shared commonalities despite multiple etiologies. Pain 2005;113:251–4.
- [4] Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389-400.
- [5] Kingery SW. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain 1997;73:123–9.
- [6] Koltzenburg M. Painful neuropathies. Curr Opin Neurol 1998;11:515–21.
 [7] Kalso E, Edward JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: a systematic review of efficacy and safety. Pain 2004;112:372–80.
- [8] Wallace MS. Diagnosis and treatment of neuropathic pain. Curr Opin Anaesth 2005;18:548–54.
- [9] Davis JL, Lewis SB, Gerich JE, Kaplan RA, Schultz TA, Wallin DJ. Peripheral diabetic neuropathy treated with amitriptyline and fluphenazine. J Am Med Assoc 1977;238:2291–2.
- [10] Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, et al. Advances in neuropathic pain: diagnosis, mechanisms and treatment recommendations. Arch Neurol 2003;60:1524–34.
- [11] Owen RT. Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today 2007;43:857–63.
- [12] Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: doubleblind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65:39–44.
- [13] Beniczky S, Tajti J, Tímea Varga E, Vécsei L. Evidence-based pharmacological treatment of neuropathic pain syndromes. J Neural Transm 2005;112: 735–49.
- [14] Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 2000;108:2–8.
- [15] Linde K, Mulrow CD, Berner M, Egger M. St. John's Wort for depression. Cochrane Database Syst Rev 2005;2:CD000448.
- [16] Greeson JM, Sanford B, Monti DA. St. John's Wort (*Hypericum perforatum*): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology 2001;153:402–14.

- [17] Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H. Inhibition of monoamine oxidase by hypericin. Planta Med 1984;50:272–4.
- [18] Kubin A, Wierrani F, Burner U, Alth G, Grünberger W. Hypericin the facts about a controversial agent. Curr Pharmac Des 2005;11:233–53.
- [19] Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Muller WE. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci 1998;63:499–510.
- [20] Chatterjee SS, Noldner M, Koch E, Erdelmeier C. Antidepressant activity of *Hypericum perforatum* and hyperforin: the neglected possibility. Pharmacopsychiatry 1998;31(Suppl. 1):7–15.
- [21] Muller WE, Singer E, Wonnemann M, Hafner U, Rolli M, Schafer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 1998;31(Suppl. 1):16–21.
- [22] Gobbi M, Dalla Valle F, Ciapparelli C, Diomede L, Morazzoni P, Verotta L, et al. Hypericum perforatum L. extract does not inhibit 5-HT transporter in the rat brain. N-S Arch Pharmacol 1999;360:262–9.
- [23] Nathan P. The experimental and clinical pharmacology of St. John's Wort (Hypericum perforatum L.). Mol Psychiatry 1999;4:333-8.
- [24] Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988;33:87–107.
- [25] Cavaletti G, Tredici G, Petruccioli MG, Dondè E, Tredici P, Marmiroli P, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001;37:2457–63.
- [26] Galeotti N, Bartolini A, Ghelardini C. The phospholipase C-IP₃ pathway is involved in muscarinic antinociception. Neuropsychopharmacology 2003;28: 888–97.
- [27] Brolis M, Gabetta B, Fuzzati N, Pace R, Panzeri F, Peterlongo F. Identification by high-performance liquid chromatography-diode array detection-mass spectrometry and quantification by high performance liquid chromatography–UV absorbance detection of active constituents of *Hypericum perforatum*. J Chromatogr A 1998;825:9–16.
- [28] Sindrup SH, Madsen C, Bach FW, Gram LF, Jensen TS. St. John's Wort has no effect on pain polyneuropathy. Pain 2000;91:361–5.
- [29] Uchida S, Hirai K, Hatanaka J, Hanato J, Umegaki K, Yamada S. Antinociceptive effects of St. John's Wort, *Harpagophytum procumbens* extract and grape seed proantocyanidins extract in mice. Biol Pharm Bull 2008;31:240–5.
- [30] Simmen U, Schweitzer C, Burkard W, Schaffner W, Lundstrom K. Hypericum perforatum inhibits the binding of mu- and kappa-opioid receptor expressed with the Semliki Forest virus system. Pharm Acta Helv 1998;73:53–6.
- [31] Simmen U, Higelin J, Berger-Büter K, Schaffner W, Lundstrom K. Neurochemical studies with St. John's Wort in vitro. Pharmacopsychiatry 2001;34(Suppl. 1):S137–42.
- [32] Tedeschi E, Menegazi M, Margotto D, Suzuki H, Forstermann U, Kleinert H. Anti-inflammatory actions of St. John's Wort: inhibition of human inducible nitric-oxide synthase expression by down-regulating signal transducer and activator of transcription-1 alpha (STAT-1 alpha) activation. J Pharmacol Exp Ther 2003;307:254–61.
- [33] Meotti FC, Luiz AP, Pizzolatti MG, Kassuya CAL, Calixto JB, Santos AR. Analysis of the antinociceptive effect of the flavonoid myricitrin: evidence for a role of the L-arginine nitric-oxide and protein kinase C pathways. J Pharmacol Exp Ther 2006;316:789–96.
- [34] Takahashi I, Nakanishi S, Kobayashi E, Nakano H, Suzuki K, Tamaoki T. Hypericin and pseudohypericin specifically inhibit protein kinase C: possible relation to their antiretroviral activity. Biochem Biophys Res Commun 1989;165:1207–12.
- [35] Ferriola PC, Cody V, Middleton Jr E. Protein kinase C inhibition by plant flavonoids. Biochem Pharmacol 1989;38:1617-24.
- [36] Velàzquez KT, Mohammad H, Sweitzer SM. Protein kinase C in pain: involvement of multiple isoforms. Pharmacol Res 2007;55:578–89.
- [37] Way KJ, Chou E, King GL. Identification of PKC-isoforms-specific biological actions using pharmacological approaches. Trends Pharmacol Sci 2000;21: 181–7.
- [38] Malmberg AB, Chen C, Tonegawa S, Basbaum AI. Preserved acute pain and reduced neuropathic pain in mice lacking PKCγ. Science 1997;278:279–83.
- [39] Dina OA, Chen X, Reichling D, Levine JD. Role of protein kinase C ϵ and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience 2000;108:507–15.
- [40] Nishizuka Y. Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992;258:607–15.
- [41] Kim HP, Park H, Son KH, Chang HW, Kang SS. Biochemical pharmacology of biflavonoids: implications for anti-inflammatory action. Arch Pharm Res 2008;31:265–73.
- [42] Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacological management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237–51.